Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SCNI 
Scinai Immunotherapeutics Ltd (SCNI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: SCNI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $700
1 Year Target Price $700
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.06% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.20M USD | Price to earnings Ratio - | 1Y Target Price 700 |
Price to earnings Ratio - | 1Y Target Price 700 | ||
Volume (30-day avg) 1 | Beta 2.09 | 52 Weeks Range 1.90 - 8.92 | Updated Date 07/4/2025 |
52 Weeks Range 1.90 - 8.92 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 728.88% | Operating Margin (TTM) -1098.54% |
Management Effectiveness
Return on Assets (TTM) -34.92% | Return on Equity (TTM) 177.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7951821 | Price to Sales(TTM) 3.35 |
Enterprise Value 7951821 | Price to Sales(TTM) 3.35 | ||
Enterprise Value to Revenue 12.08 | Enterprise Value to EBITDA 1.01 | Shares Outstanding 999919 | Shares Floating 2442673465 |
Shares Outstanding 999919 | Shares Floating 2442673465 | ||
Percent Insiders 18.22 | Percent Institutions 26.55 |
Upturn AI SWOT
Scinai Immunotherapeutics Ltd
Company Overview
History and Background
Scinai Immunotherapeutics Ltd. (SCNI) is a biopharmaceutical company primarily focused on developing and commercializing innovative biological products and platforms. While historical details are limited in readily available public sources, the company's focus has been on building a diverse portfolio of therapeutic candidates, including those targeting autoimmune diseases and cancer.
Core Business Areas
- Development and Commercialization of Immunotherapies: Focuses on research, development, and commercialization of innovative immunotherapeutic products to treat diseases with unmet needs. This involves pre-clinical, clinical trials, and potential manufacturing.
- Partnering and Licensing: Collaborating with other pharmaceutical and biotech companies through licensing agreements or partnerships to expand product reach and development capabilities.
Leadership and Structure
Information on specific individuals is limited, but the company likely operates with a CEO, CFO, CSO, and a board of directors overseeing strategy and operations. The organizational structure likely includes departments for research and development, clinical trials, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- IL-18 Binding Protein (IL-18BP) Platform: IL-18BP's antagonists are thought to be effective and have shown potential in treating autoimmune and inflammatory conditions. Market share data is not readily available. Competitors include companies developing similar interleukin inhibitors and other autoimmune treatments. Potential competitors are major pharmaceutical companies in the autoimmune space.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The immunotherapy market is experiencing significant growth due to advancements in understanding the immune system and developing targeted therapies.
Positioning
Scinai Immunotherapeutics Ltd aims to carve a niche by focusing on developing novel immunotherapies. They are positioning themsleves to capitalize on unmet needs. Competitive advantages would rely on the efficacy and uniqueness of the technology platform and speed to market.
Total Addressable Market (TAM)
The global immunotherapy market is projected to reach hundreds of billions of USD. Scinai Immunotherapeutics Ltd's position relative to this TAM is currently small, but potential products could increase its portion of the TAM with effective development and comercialization.
Upturn SWOT Analysis
Strengths
- Proprietary IL-18BP technology platform
- Focus on immunotherapeutic development
- Potential for partnerships and licensing agreements
Weaknesses
- Limited financial resources
- Dependence on successful clinical trials
- Smaller size compared to major pharmaceutical companies
- Limited revenue
Opportunities
- Growing demand for immunotherapies
- Potential for breakthrough treatments
- Strategic partnerships to expand reach and funding
- Increasing prevalence of autoimmune diseases
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles and approval delays
- Patent expirations
Competitors and Market Share
Key Competitors
- ABBV
- JNJ
- MRK
Competitive Landscape
Scinai Immunotherapeutics Ltd faces intense competition from larger pharmaceutical companies with greater resources and established market presence. Scinai Immunotherapeutics Ltd advantages would rely on the innovation and efficacy of its technology and it niche focus. Scinai Immunotherapeutics Ltd disadvantages include the limited amount of funding and resources to compete.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is largely dependent on its technological advancements, collaborations, and clinical trial milestones.
Future Projections: Future projections are speculative and based on the success of its clinical trials, regulatory approvals, and ability to secure funding and partnerships. Analyst estimates are not readily available.
Recent Initiatives: Recent strategic initiatives would likely include advancing clinical trials for its lead compounds and securing partnerships to fund development and commercialization.
Summary
Scinai Immunotherapeutics Ltd. is a small biopharmaceutical company with a focus on immunotherapy, especially targeting autoimmune diseases. Its strength lies in its novel IL-18BP platform, but it faces challenges with limited financial resources and competition from larger companies. Successful clinical trials and strategic partnerships are essential for its growth. The company must look out for the long and rigorous regulatory path to have a successful and profitable product line.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Websites
- SEC Filings
- Industry Reports
- Financial News Outlets
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scinai Immunotherapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-05-12 | CEO & Director Mr. Amir Reichman M.B.A., M.Sc. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | Website https://www.scinai.com |
Full time employees 31 | Website https://www.scinai.com | ||
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.